MedTrace Logo

Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions

NCT00832481 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-08-25

No results posted yet for this study

Summary

This is a 17 week, randomized, single center, open-label, parallel-group study to compare glucose excursions and other efficacy and safety parameters of repaglinide thrice daily or metformin thrice daily in newly diagnosed type 2 diabetes subjects in China.

Conditions

Interventions

DRUG

Repaglinide

Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet

DRUG

Metformin

2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Chunlin Li, M.D&Ph.D · PLA General Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832481 on ClinicalTrials.gov